ALDX
Aldeyra Therapeutics, Inc.
1.20$
-9.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.7% | -4.7% | -10.8% | -6.9% | -10.8% | -10.9% | -8.8% | -8.4% | -7.4% | -7.7% | -28.5% | |
| – | +0.4% | -4.7% | -10.8% | -7.1% | -10.8% | -10.9% | -8.8% | -8.4% | -7.3% | -7.7% | -28.5% | |
| – | -0.4% | -28.2% | -30.7% | -4.1% | -20.0% | -7.7% | -18.1% | +43.9% | +18.0% | -7.2% | -30.6% | |
| – | -0.4% | -6.9% | -9.6% | -6.3% | -10.3% | -11.0% | -9.0% | -8.1% | -7.0% | -7.2% | -30.6% | |
| – | – | – | -20.0% | +0.0% | – | – | – | – | – | – | – | |
| – | +17.5% | -2.3% | -0.5% | +16.2% | +4.3% | -11.9% | +0.3% | -3.8% | -2.6% | -12.5% | -60.3% | |
| – | +3.0% | -2.6% | +27.3% | -37.8% | +8.4% | -23.2% | +106.7% | -3.5% | -2.4% | -12.5% | -60.3% | |
| – | +13.7% | +0.4% | +0.3% | -96.5% | -44.2% | -15.7% | +5,936.0% | +0.4% | +0.4% | -0.1% | -99.1% | |
| – | +441.3% | -79.1% | -9.2% | -26.5% | -3.5% | +91.8% | +320.4% | -99.1% | +1,080.5% | -10.8% | -2.7% | |
| – | – | – | – | – | +0.0% | +0.7% | – | – | – | – | – | |
| – | -2.6% | -5.3% | -13.3% | -13.4% | -16.6% | -10.4% | -13.1% | -10.9% | -10.1% | -4.7% | -10.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | +0.4% | +0.0% | +0.2% | -0.1% | +0.7% | +0.3% | +0.1% | +0.1% | +0.3% | +0.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.